Methotrexate prophylaxis for persistent ectopic pregnancy after conservative treatment by salpingostomy

Area of Science:

• Reproductive Endocrinology
• Gynecologic Surgery
• Pharmacology

Background:

• Ectopic pregnancy remains a significant concern in women's reproductive health.
• Linear salpingostomy is a conservative surgical approach for unruptured ectopic pregnancy.
• Persistent ectopic pregnancy after salpingostomy necessitates extensive postoperative monitoring.

Purpose of the Study:

• To evaluate the efficacy of prophylactic methotrexate in reducing persistent ectopic pregnancy post-salpingostomy.
• To assess the safety and impact on monitoring of this prophylactic regimen.

Main Methods:

• A randomized controlled trial involving 129 women undergoing linear salpingostomy.
• Exclusion criteria included anemia, renal, or liver disease.
• Prophylaxis group received a single intramuscular dose of methotrexate (1 mg/kg) within 24 hours postoperatively; control group received no treatment.
• Serial serum beta-hCG monitoring was performed until levels normalized (<15 mIU/mL).
• Persistent ectopic pregnancy defined as inadequate beta-hCG decline.

Main Results:

• 116 women completed follow-up; 10 (8.6%) had persistent ectopic pregnancy.
• Incidence was significantly lower in the prophylaxis group (1.9%) compared to the control group (14.5%) (P < .05).
• Relative risk of persistent ectopic pregnancy was reduced by 87% with prophylactic methotrexate (RR = 0.13).
• Mild, transient side effects were reported in 5.5% of the prophylaxis group.

Conclusions:

• A single prophylactic dose of systemic methotrexate significantly decreases the incidence of persistent ectopic pregnancy after linear salpingostomy.
• This approach is safe and effective, potentially reducing the need for intensive postoperative surveillance.
• Prophylactic methotrexate offers a valuable strategy for optimizing conservative management of unruptured ectopic pregnancy.